Development and Evaluation of Novel 68 Ga/ 177 Lu-Labeled PSMA Inhibitors with Enhanced Pharmacokinetics and Tumor Imaging for Prostate Cancer
Molecular Pharmaceutics · 03.03.2025 · 22 (3) · 1584-1597
DOI: 10.1021/acs.molpharmaceut.4c01302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 14.02.2025. Verfasst von Haiyang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Jiangyang District, Luzhou, Sichuan 646000, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Gallium Radioisotopes, Glutamate Carboxypeptidase II, Lutetium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Southwest Medical University, Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Jiangyang District, Luzhou, Sichuan 646000, China.
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Jiangyang District, Luzhou, Sichuan 646000, China.
- Department of Pharmaceutics, School of Pharmacy, Southwest Medical University, Jiangyang District, Luzhou, Sichuan 646000, China.
- Institute of Nuclear Medicine, Southwest Medical University, Jiangyang District, Luzhou, Sichuan 646000, China.
- Department of Nuclear Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.
ORCID-Profile: Ping Cai, Yue Chen, Zhijun Zhou
Förderung
- Southwest Medical University
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Liu, Y., Yuan, H., Cai, P., Wu, T., Yang, Z., Nie, J., Zhang, W., Huang, Z., Liu, N., Chen, Y., & Zhou, Z. (2025). Development and Evaluation of Novel 68 Ga/ 177 Lu-Labeled PSMA Inhibitors with Enhanced Pharmacokinetics and Tumor Imaging for Prostate Cancer. Molecular Pharmaceutics, 22(3), 1584-1597. https://doi.org/10.1021/acs.molpharmaceut.4c01302
Vancouver
Li H, Liu Y, Yuan H, Cai P, Wu T, Yang Z, et al. Development and Evaluation of Novel 68 Ga/ 177 Lu-Labeled PSMA Inhibitors with Enhanced Pharmacokinetics and Tumor Imaging for Prostate Cancer. Molecular Pharmaceutics. 2025;22(3):1584-1597. doi:10.1021/acs.molpharmaceut.4c01302
BibTeX
@article{Li2025,
author = {Li, Haiyang and Liu, Yang and Yuan, Hongmei and Cai, Ping and Wu, Tongtong and Yang, Zhicong and Nie, Jiaqi and Zhang, Wei and Huang, Zhanwen and Liu, Nan and Chen, Yue and Zhou, Zhijun},
title = {Development and Evaluation of Novel 68 Ga/ 177 Lu-Labeled PSMA Inhibitors with Enhanced Pharmacokinetics and Tumor Imaging for Prostate Cancer},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {3},
pages = {1584--1597},
doi = {10.1021/acs.molpharmaceut.4c01302}
}
EUVIMED